Abstract
Purpose :
To invest the changes in retinal circulatory dynamics in patients with non-ischemic CRVO treated with Aflibercept vitreous injection (IVA) using retinal oximetry and laser speckle flowgraphy (LSFG).
Methods :
17 eyes in 17 patients with untreated nonischemic CRVO who underwent IVA. Retinal blood flow and retinal vascular resistance were measured with LSFG and retinal oxygen saturation were measured with Oxymap T1 at before treatment, 1, 3, 6, 9, and 12 months after treatment.
Results :
Mean retinal venous oxygen saturation (V-SO2) was 37.8±10.9%, 43.9±11.0%, 46.3±11.2%, 44.2±11.7%, 46.6±11.9% and 49.0±9.8% at before treatment, 1, 3, 6, 9 and 12 months after treatment.
With LSFG, mean blur rate (MBR) was 22.2±8.1, 22.3±8.0, 22.7±10.1, 24.2±11.2, 22.2±9.8, 21.7±11.0, TCR was 1.11±0.52, 0.84±0.38, 0.92±0.54, 1.07±0.57, 0.99±0.53, 1.22±0.60 in the CRVO eyes.
V-SO2 decreased and total capillary resistance (TCR) increased in CRVO eyes, and V-SO2 increased and TCR decreased after IVA treatment, showing a negative correlation between V-SO2 and TCR at 6, 9 and 12 months.
Conclusions :
In CRVO, increased vascular resistance causes stasis of retinal blood flow, which in turn increases oxygen diffusion and increases V-SO2. It can be inferred that treatment decreases vascular resistance, thereby decreasing oxygen diffusion and V-SO2.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.